Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)─directed antibody-drug conjugate (ADC), plus pembrolizumab: Updated results from the phase 1 study (SGNB6A-001). Impact of MET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results